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Abstract
Background: Acute myeloid leukemia (AML) is an immunophenotypically heterogenous malignant disease, in which
CD34 positivity is associated with poor prognosis. CD34
+ AML cells are 10-15-fold more resistant to daunorubicin
(DNR) than CD34
- AML cells. Curcumin is a major component of turmeric that has shown cytotoxic activity in
multiple cancers; however, its anti-cancer activity has not been well studied in DNR-insensitive CD34
+ AML cells. The
aim of this study was to therefore to explore curcumin-induced cytotoxicity in DNR-insensitive CD34
+ AML cell lines
(KG1a, Kasumi-1), DNR-sensitive U937 AML cells, and primary CD34
+ AML bone-marrow-derived cells.
Methods: Primary human CD34
+ cells were isolated from peripheral blood mononuclear cells or bone marrow
mononuclear cells using a CD34 MicroBead kit. The growth inhibitory effects of curcumin were evaluated by MTT
and colony-formation assays. Cell cycle distribution was examined by propidium iodide (PI) assay. Apoptosis was
analyzed by Wright-Giemsa, Hoechst 33342 and Annexin-V/PI staining assays. The change in mitochondrial
membrane potential (MMP) was examined by JC-1 staining and flow cytometry. Expression of apoptosis-related
proteins was determined by reverse transcription-polymerase chain reaction and Western blotting. Short interfering
RNA (siRNA) against Bcl-2 was used in CD34
+ KG1a and Kasumi-1 cells incubated with/without DNR.
Results: Curcumin inhibited proliferation and induced apoptosis and G1/S arrest in both DNR-insensitive KG1a,
Kasumi-1 and DNR-sensitive U937 cells. Curcumin-induced apoptosis was associated with reduced expression of
both Bcl-2 mRNA and protein, subsequent loss of MMP, and activation of caspase-3 followed by PARP degradation.
Curcumin synergistically enhanced the cytotoxic effect of DNR in DNR-insensitive KG1a and Kasumi-1 cells,
consistent with decreased Bcl-2 expression. Accordingly, siRNA against Bcl-2 increased the susceptibility of KG1a
and Kasumi-1 cells to DNR-induced apoptosis. More importantly, curcumin suppressed Bcl-2 expression, selectively
inhibited proliferation and synergistically enhanced the cytotoxicity of DNR in primary CD34
+ AML cells, while
showing limited lethality in normal CD34
+ hematopoietic progenitors.
Conclusion: Curcumin down-regulates Bcl-2 and induces apoptosis in DNR-insensitive CD34
+ AML cell lines and
primary CD34
+ AML cells.
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Acute myeloid leukemia (AML) is an immunophenotypi-
cally heterogenous malignant disease, in which CD34 posi-
tivity has been significantly correlated with a lower
complete response (CR) rate, drug resistance and poor
outcome [1-3]. Treatment of AML has generally consisted
of a combination of cytarabine and an anthracycline such
as daunorubicin (DNR), or the anthracenedione mitoxan-
trone [4]. Although conventional chemotherapy regimens
induce CR in 65-80% of newly diagnosed AML patients,
most patients who achieve a CR relapse within 2 years
from diagnosis [5]. At relapse, blast cells usually display a
more immature phenotype, with one of the most common
antigenic changes being a gain in expression of the stem
cell antigen CD34 [6,7]. This is reflected in the resistance
of these immature phenotype CD34
+ AML progenitors to
current chemotherapies.
CD34
+ AML cells are 10-15-fold more resistant to
DNR than CD34
- AML cells [8]. CD34
+ KG1a and TF-1
AML cell lines are 30-40 fold more resistant to mitox-
antrone than more mature HL-60 and U937 cells, and
this resistance appears to be associated with the lack of
apoptosis [9]. Increasing evidence indicates that CD34
+
AML cells are less sensitive to spontaneous apoptosis
and have higher levels of Bcl-2 and Bcl-xl gene and pro-
tein expression than the CD34
- subpopulation [6,10-12].
CD34 positivity has been reported to be another indica-
tor of poor prognosis in AML [3,12], and use of more
effective drugs to eliminate this early immature CD34
+
AML cell subpopulation might therefore improve the
outcome of AML.
DNR is one of the most commonly used anti-leukemia
agents. Bcl-2 overexpression can block DNR-induced
apoptosis in more mature U937 AML cells [13]. The
anti-apoptotic proteins Bcl-2 and Bcl-xl also contribute
to the survival and chemoresistance of quiescent leuke-
mia CD34
+ cells [14]. These findings suggest that Bcl-2
plays a critical role in CD34
+ AML cell survival and that
agents aimed at down-regulating Bcl-2 protein might be
e f f e c t i v ef o rt h et r e a t m e n to fD N R - i n s e n s i t i v eC D 3 4
+
AML.
Curcumin, a major yellow pigment in turmeric, has
been proven to be a powerful therapeutic drug [15,16].
Curcumin induces apoptosis in a variety of tumor cells,
including more mature HL-60 and U937 cell lines,
through activation of caspase-3, cytochrome c release,
and down-regulation of Bcl-2 [17-20]. Curcumin inhibits
proliferation in a variety of cancer cells through target-
ing multiple cellular signaling pathways [21], including
the mitogen-activated protein kinase [22], nuclear factor
kappaB [23], phosphoinositide-3 kinase/Akt/mammalian
target of rapamycin [24,25], Wnt [26], and Notch-
mediated signaling pathways [27]. Curcumin has also
been found to be a powerful chemosensitizing agent in
tumor cells. It demonstrated no major toxicities in
phase I and II clinical studies at doses of up to 8 g/day
[28,29]. However, the cytotoxic effects of curcumin in
DNR-insensitive CD34
+ immature AML cells remain
unclear.
In this study, we examined the cytotoxic efficiency and
molecular mechanisms underlying the anticancer activity
of curcumin in both DNR-insensitive CD34
+ immature
AML cell lines and in primary CD34
+AML cells.
Methods
Materials
Curcumin (Sigma, St. Louis, MO) was dissolved in
dimethyl sulfoxide (DMSO) to prepare a 100-mM stock
solution that was stored at -20°C. DNR was purchased
from Pharmacia & Upjohn SpA (Milan, Italy). Annexin-V
assay kit was purchased from Molecular Probes (Eugene,
OR, USA). Anti-cleaved PARP, cleaved caspase-3, and
Bcl-2 antibodies were purchased from Cell Signaling
Technologies (Beverly, MA, USA). Anti-GAPDH anti-
body and goat anti-rabbit/mouse-horseradish peroxidase
(HRP)-conjugated secondar ya n t i b o d yw e r ep u r c h a s e d
from Protein Tech Group (Chicago, IL, USA). JC-1 kit
was purchased from Beyotime (China). CD34-PE and
IgG1-PE monoclonal antibodies were purchased from BD
Biosciences (San Jose, CA, USA). CD34 MicroBead kit
was purchased from Miltenyi biotec (Auburn, CA, USA).
Cell lines, primary samples, and cell culture
KG1a and Kasumi-1 cell lines were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkul-
turen GmbH (DSMZ) (Braunschweig, Germany) and
grown in RPMI 1640 medium (Gibco; Invitrogen, Carls-
bad, CA, USA) supplemented with 20% (v/v) fetal bovine
serum (FBS; Hyclone, Logan, UT). According to immu-
nological studies by DSMZ and others [30,31], KG1a and
Kasumi-1 cells are characterized by high expression of
CD34 surface antigen. U937 cells were obtained from the
American Type Culture Collection (ATCC) and grown in
RPMI 1640 medium supplemented with 10% FBS. Cells
were cultured at 37°C in a humidified atmosphere con-
taining 5% CO2. Control cultures received an equivalent
amount of DMSO only. Bone marrow mononuclear cells
(BMMCs) or mobilized peripheral blood mononuclear
cells (PBMCs) were obtained from 9 newly diagnosed
AML patients and 8 healthy donors. All donors provided
written informed consent, and the study had the approval
of the Institute Research Ethics Committee at Sun Yan-
sen University, in accordance with the Declaration of
Helsinki. Patient characteristics are shown in Table 1.
PBMCs and BMMCs were enriched by Ficoll-Hypaque
density gradient centrifugation and isolated using a CD34
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Page 2 of 15MicroBead kit. BMMCs and PBMCs were stained with
PE-conjugated anti-CD34 to determine the purity of
CD34
+ cells.
MTT assay
Viability was assessed by MTT assay. Briefly, 1.0×10
4
cells were incubated in triplicate in a 96-well plate in the
presence or absence of the indicated test samples in a
final volume of 0.2 ml for various lengths of time at 37°C.
Thereafter, 20 μl MTT solution (5 mg/ml in PBS) was
then added to each well. After 4-h incubation at 37°C,
150 μl DMSO was added. Finally the plates were shaken
and the optical density at 490 nm was measured using a
multiwell plate reader (Microplate Reader; Bio-Rad,
Hercules, CA). Percent cell viability was calculated as cell
viability of the experimental samples/cell viability of the
control samples × 100. At least three independent experi-
ments were performed.
Colony-forming assay
Treated and untreated cells were cultured in RPMI 1640
medium supplemented with 0.9% methylcellulose and
20% FBS at 37°C in 5% CO2. The colonies (containing
50 or more cells) were counted by light microscopy
after 14 days. All semi-solid cultures were performed in
triplicate. Three independent experiments were
performed.
Wright-Giemsa staining
Morphological signs of apoptosis were detected by
Wright-Giemsa staining. Cells were treated with 0-80 μM
curcumin for 24 h. Smears of control and treated cells
were stained with Wright-Giemsa solution for 25 min,
rinsed with distilled water and air dried. Cell morphology
was studied by light microscopy.
Hoechst 33342 staining
Nuclear fragmentation was examined by Hoechst 33342
(Sigma). Cells treated with 0-80 μMc u r c u m i nf o r2 4h
were washed and stained with Hoechst 33342 (10 μg/ml)
for 15 min at 37°C. Slides were viewed using a fluores-
cence microscope.
Measurement of apoptosis by Annexin V analysis
An Annexin V-binding assay was used according to the
manufacturer’s instructions. Briefly, approximately
5×10
5/ml cells in 6-well plates were treated with various
concentrations of the indicated test samples. The cells
were harvested and used for Annexin V-Alexa Fluor-
488/PI staining. The stained cells were analyzed by flow
cytometry to determine the percentages of AnnexinV
+/PI
- (early apoptosis) and AnnexinV
+/PI
+ (late apopto-
sis) cells.
Cell cycle analysis
Cell cycle was analyzed by flow cytometry. Approxi-
mately 5 × 10
5/ml cells in 6-well plates were treated
with various concentrations of curcumin for 24 h. Cell
cycle analysis was performed using the CycleTEST™
PLUS DNA kit (BD Biosciences).
Detection of mitochondrial membrane potential (MMP,
Δψm) using JC-1
MMP was estimated by flow cytometry after staining
with JC-1 fluorescent dye. When the cell is in a normal
state, MMP is high and JC-1 predominantly appears as
red fluorescence. When the cell is in an apoptotic or
necrotic state, the MMP is reduced and JC-1 appears as a
monomer indicated by green fluorescence. A change in
the florescence from red to green indicates a decrease in
the MMP. Approximately 5×10
5/ml cells in 6-well plates
were treated with various concentrations of curcumin for
24 h. The cells were then washed with PBS and incubated
with JC-1 working solution for 20 min at 37°C in the
dark. Cells were washed with PBS and resuspended in
500 μl PBS. The stained cells were analyzed by flow cyto-
metry to determine the change in the florescence from
red to green.
Table 1 Characteristic of patients
Patient# Age/Sex FAB WBC(*109/L) %CD34 in BMC* Source Cytogenetics
P1 35 Y/M M2 9.09 67.3 BM 46 XY
P2 60 Y/M M2b 15.80 72.1 BM 46 XY, t(8;21),AML1/ETO #
P3 46 Y/M M5 12.00 56.0 BM 46 XY
P4 17 Y/M M5b 3.39 89.1 BM 46 XY
P5 28 Y/M M2b 11.37 76.3 BM 46 XY, t(8;21),AML1/ETO #
P6 20 Y/M M1 10.03 70.1 BM 46 XY
P7 78 Y/M M4 101.08 52.1 PB 46 XY inv (16)(p13q22)
P8 72 Y/F M2a 1.95 31.5 PB 46 XX
P9 54 Y/M M1 103.79 62.8 BM 46 XY
P patient, Y year, M male, FAB French-American-British, WBC white blood cells, BMC bone marrow cells, BM bone marrow, PM peripheral blood.*Percentage of
CD34
+ cells in bone marrow cells of AML patients before sorting.
# The t (8; 21) (q22; q22) chromosomal translocation gives rise to the AML1/ETO fusion
oncoprotein.
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polymerase chain reaction (RT-PCR)
Total RNA was extracted using Trizol isolation reagent
(Invitrogen, USA). Reverse transcription was performed
using a reverse transcriptase first strand cDNA synthesis
kit (Takara, Japan). The sequences of the sense and anti-
sense primers were: 5’-CTGGTGGACAACATCGC-3’
(sense) and 5’-GGAGAAATCAAACAGAGGC-3’ (anti-
sense) for Bcl-2, 5’-TGACTTTTCCTGTGAACTCT-3’
(sense) and 5’-GCCTTTCATTCGTATCAAGA-3’ (anti-
sense) for c-IAP-1, 5’-GCAGGGTTTCT TTATACTG-3’
(sense) and 5’-TGTCCCTTCTGTTCTAACAG-3’ (anti-
sense) for XIAP [32], 5’-GTGGACATCCGCAAAGAC-
3’ (sense) and 5’-GAAAGGGTGTAA CGCAACT-3’
(anti-sense) for b-actin. The PCR conditions were as fol-
lows: for c-IAP-1 and XIAP, 94°C for 1 min, 62°C for
1 min, and 72°C for 1 min; for Bcl-2, 94°C for 30 s,
62°C for 30 s, 72°C for 10 s; and for b-actin: 94°C for
30 s, 55°C for 30 s, 72°C for 1 min. Thirty cycles of
amplification were used. PCR (10 μl) products were ana-
lyzed by electrophoresis on 2% (w/v) agarose gel.
Western blot analysis
Total cellular proteins were isolated with lysis buffer
(20 mM Tris, pH 7.5; 150 mM NaCl; 0.25% NP40;
2 . 5m Ms o d i u mp y p r o p h o s p h a t e ;1m ME G T A ,1m M
EDTA; 1 mM b-glycerophosphate; 1 mM Na3VO4;1m M
PMSF; 1 μg/ml leupeptin). Equal amounts of protein were
subjected to 10% or 15% sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis and transferred to nitrocellulose
membranes. The membranes were treated with primary
antibodies overnight at 4°C and incubated with a HRP-
conjugated anti-mouse or anti-rabbit secondary antibody
at room temperature for 1 h. The protein bands were
visualized using an enhanced chemiluminescence reagent
(Pierce Biotechnology, USA), according to the manufac-
turer’si n s t r u c t i o n s .
Short interfering RNA (siRNA) transfection
KG1a and Kasumi-1 cells were seeded onto 6-well plates
for 24 h before transfection. Control scrambled siRNA
was synthesized and purchased from GenePharma (Shang-
hai Co. Ltd., China). SiRNA Bcl-2 (50 nM): 5’-GGGA-
GAUAGUGAUGAAG UAUU-3’ [33] or control scramble
sequences were transfected using Lipofectamine 2000
reagent (Invitrogen), according to the manufacturer’sp r o -
tocol. Briefly, for each well, 5 μl Lipofectamine 2000 was
diluted in 250 μl Opti-MEM medium (Invitrogen). The
mixture was gently added to a solution containing siRNA
in 250 μl Opti-MEMI medium and incubated for 20 min.
The mixture was then added to the plates. After transfec-
tion with siRNA for 24 h, cells were harvested for further
assay.
Statistical analysis
Data were presented as mean ± SD. One-way ANOVA fol-
lowed by Bonferroni multiple comparison was performed
to assess the differences between two groups under multi-
ple conditions. If the data failed the normality test, the
Kruskal-Wallis one-way ANOVA on ranks was used. A
value of p < 0.05 was considered statistically significant.
Both Calcusyn software (Biosoft, Ferguson, MO, USA)
[34,35] and Jin’s formula [36] were used to evaluate the
synergistic effects of drug combinations. Jin’s formula is
g i v e na s :Q=E a+b / ( E a+E b - E a×E b ) .E a + br e p r e s e n t s
the cell proliferation inhibition rate of the combined
drugs, while Ea and Eb represent the rates for each drug
respectively. A value of Q = 0.85-1.15 indicates a simple
additive effect, while Q > 1.15 indicates synergism. Combi-
nation index (CI) plots were generated using CalcuSyn
software. A value of CI < 1 indicates synergism.
Results
CD34
+ KG1a and Kasumi-1cells were insensitive to DNR
KG1a, Kasumi-1 and U937 AML cells were stained with
PE-conjugated CD34 antibody and subjected to flow
cytometry to determine the purity of CD34
+ cells. The
percentages of CD34
+ cells were 99.43 ± 0.60% in KG1a
cells, 96.67 ± 0.11% in Kasumi-1 cells, but CD34
+ was
absent in U937 cells (Figure 1A). After treatment of
these three cell lines with different concentrations of
DNR for 48 h, MTT and apoptosis analyses showed that
DNR inhibited proliferation and induced apoptosis in
more mature U937 cells, but not in immature CD34
+
KG1a or Kasumi-1 cell lines (Figure 1B, C). This was in
accord with previous studies indicating that CD34
+
AML cells were insensitive to DNR. The concentration
of DNR used in this study was clinically achievable in
patients [37,38].
Curcumin suppressed cell growth and induced G1/S cell
cycle arrest in both DNR-insensitive and -sensitive AML
cell lines
KG1a, Kasumi-1 and U937 cell lines were exposed to
curcumin (0-100 μM) for 24, 48, 72 and 96 h. The cyto-
toxic effects of curcumin were determined by MTT
assay. Curcumin had a significant cytotoxic effect in all
tested cell lines in both dose- and time-dependent man-
ners (Figure 2B, C, D). The IC50 values at 24, 48, 72,
and 96 h were 230.5, 86.9, 60.0, and 35.7 μMf o rK G 1 a ,
68.5, 46.6, 28.8, and 23.5 μM for Kasumi-1, and 58.3,
26.0, 10.6, and 4.4 μM for U937 cells, respectively. The
antiproliferative effects of curcumin in these cell lines
were further determined using clonogenic assays. Curcu-
min inhibited clonogenic growth in a dose-dependent
manner, and completely inhibited colony formation at a
dose as low as 20 μM (Figure S1A, B, Additional file 1).
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Page 4 of 15Cell cycle distributions in KG1a, Kasumi-1, and U937
cells were examined after treatment with curcumin for
24 h. As shown in Figure 2E, treatment of KG1a cells
with 80 μM curcumin resulted in a significant increase
in the percentage of cells in the G1 phase, from 46-62%,
and a decrease in the percentage of cells in the S phase,
from 39-23%. Similar results were found for Kasumi-1
and U937 cells. These results demonstrated that curcu-
min induced G1/S arrest in both DNR-insensitive and
-sensitive AML cell lines.
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Figure 1 CD34
+ KG1a and Kasumi-1cells were insensitive to DNR.( A) KG1a, Kasumi-1 and U937 cells were stained with PE-conjugated CD34
antibody and subjected to flow cytometry to determine the purity of CD34
+ cells. (B, C) These three cell lines were treated with different
concentrations of DNR for 48 h. MTT assay (B) was performed as described in “Methods” and apoptosis (C) was assessed by Annexin V/PI assays.
Cells in the lower right quadrant represent early apoptosis and those in the upper right quadrant represent late apoptosis. The graph displays
the means ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 (compared with control).
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Figure 2 Curcumin suppressed cell growth and induced G1/S arrest.( A) Structure of curcumin. (B, C, D) KG1a, Kasumi-1 and U937 cell lines
were treated with different concentrations of curcumin for 24, 48, 72, and 96 h. MTT assay was performed. (E) These three cell lines were treated
with different concentrations of curcumin for 24 h and analyzed for DNA content by flow cytometry, as described in “Methods.” The bar
represents means ± SD of three independent experiments.
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caspase-3 followed by PARP degradation in both DNR-
insensitive and -sensitive AML cell lines
To determine if growth inhibition induced by curcumin
was a result of apoptosis, the pro-apoptotic effect was
examined using Wright-Giemsa, Hoechst 33342 and
Annexin-V/PI staining. Both Wright-Giemsa and
Hoechst 33342 staining showed that curcumin induced
morphological changes such as cell shrinkage and nuclear
condensation, which are typical characteristics of apopto-
sis (Figure 3A; Figure S2A, Additional file 2). These mor-
phological changes were confirmed by flow cytometry.
Treatment with curcumin at 40 μMf o r2 4hr e s u l t e di n
apoptosis rates of 23.5 ± 8.8%, 36.1 ± 5.3%, and 40.1 ±
17.8% in KG1a, Kasumi-1 and U937 cells, respectively
(Figure 3B). Western blotting analysis further showed
that curcumin induced caspase-3 activation and PARP
cleavage, two hallmarks of apoptosis (Figure 3C). Both
Annexin-V/PI and Western blotting showed that curcu-
min induced apoptosis in a dose-dependent manner.
U937cells were the most sensitive to curcumin-induced
apoptosis, followed by Kasumi-1, then KG1a cells.
Curcumin decreased Bcl-2 mRNA and protein levels and
reduced MMP in both DNR-insensitive and -sensitive AML
cell lines
The mechanisms underlying curcumin-induced apopto-
sis were investigated. The IAP and Bcl-2 family play an
important role in the regulation of cell apoptosis, and
the effects of curcumin on mRNA levels of c-IAP-1,
XIAP and Bcl-2 were therefore assessed by RT-PCR. As
shown in Figure 4A, Bcl-2 mRNA levels were signifi-
cantly down-regulated in both DNR-insensitive AML
cell lines (KG1a and Kasumi-1) and in DNR-sensitive
U937 cells, while the levels of c-IAP-1 and XIAP were
unchanged. Western blotting also demonstrated that
curcumin significantly down-regulated Bcl-2 protein
levels in a dose-dependent manner (Figure 4B). These
results suggest that down-regulation of Bcl-2 could con-
tribute to curcumin-induced apoptosis.
Disruption of the function of Bcl-2 protein leads to per-
meabilization of the mitochondrial membrane [39]. We
therefore investigated the effects of curcumin on MMP
using JC-1 fluorescent dye and flow cytometry. Exposure
of the three cell lines to increasing doses of curcumin for
24 h led to a significant reduction in the MMP (Figure
4C). These results suggest that curcumin-induced apopto-
sis is mitochondria-dependent.
Curcumin synergistically enhanced the cytotoxic effect of
DNR in DNR-insensitive KG1a and Kasumi-1 cells,
associated with down-regulation of Bcl-2
To determine if curcumin could enhance the cytotoxic
activity of DNR, DNR-insensitive KG1a and Kasumi-1
cells were cultured with combinations of these two
drugs at different doses but in a constant ratio (curcu-
min to DNR: 20 μMt o0 . 1μg/ml, 40 μMt o0 . 2μg/ml,
and 80 μMt o0 . 4μg/ml, respectively) for 48 h, as
shown in Figure 5A, B and Table S1 (Additional file 3).
Both CalcuSyn software and Jin’sf o r m u l aw e r eu s e dt o
determine synergy, and the results were consistent.
With the exception of co-treatment of KG1a cells with
20 μM curcumin and 0.1 μg/ml DNR, which showed an
additive effect (CI = 1.03, Q = 0.99), co-treatment with
other doses in KG1a cells and with all doses in Kasumi-
1 cells exhibited synergistic effects. For example, the
combination of 40 μMc u r c u m i nw i t h0 . 2μg/ml DNR
in KG1a cells caused growth inhibition of 45.12%, com-
pared to curcumin (26.31%) or DNR (5.47%) alone, indi-
cating synergism (CI = 0.654, Q = 1.49). Notably, co-
treatment with 40 μMc u r c u m i na n d0 . 2μg/ml DNR
caused more attenuation of Bcl-2 protein levels than
treatment with either agent alone (Figure 5C).
Suppression of Bcl-2 with siRNA induced apoptosis and
increased the susceptibility of KG1a and Kasumi-1 cells to
DNR-induced apoptosis
To clarify if down-regulation of Bcl-2 by curcumin plays
an important role in this synergistic effect, Bcl-2 expres-
sion was suppressed by siRNA and the effect on apopto-
sis and DNR sensitivity was examined by flow cytometry.
Bcl-2 siRNA-induced apoptosis in 24 h (28.58% in KG1a
cells, 37.12% in Kasumi-1 cells) was similar to that in cur-
cumin-treated KG1a (31.71%, 60 μM, Figure 3B) and
Kasumi-1 cells (36.10%, 40 μM, Figure 3B), respectively
(Figure 6A, B). As shown in Figure 6C, suppression of
Bcl-2 by siRNA increased the susceptibility of these cell
lines to DNR-induced apoptosis (40.15% in KG1a cells
and 86.23% in Kasumi-1 cells), compared to DNR only
(3.17% in KG1a cells, 5.94% in Kasumi-1 cells). These
results suggest that suppression of Bcl-2 could contribute
to curcumin-induced apoptosis and the synergistic effect
of curcumin and DNR.
Curcumin was effective against primary CD34
+ AML cells
The cytotoxic effects of either curcumin and/or DNR on
primary CD34
+AML cells were also examined. CD34
+
cells were sorted from BMMCs or PBMCs from 9 AML
patients and 8 healthy donors. The sorted samples yielded
more than 95% CD34
+ cells with greater than 90% viabi-
lity, determined by trypan blue exclusion (Figure 7A). The
antiproliferative effects of curcumin on CD34
+ cells from
3 AML patients (patients 1, 2, 3) and 3 healthy donors
(donors 1, 2, 3) were determined by MTT assay, and com-
pared with the results of DNR treatment. CD34
+ cells
were treated with curcumin (0, 10, 20, 40, 80 μM) or DNR
( 0 ,0 . 4 ,0 . 8 ,1 . 6μg/ml) for 24 h. Curcumin significantly
inhibited proliferation of CD34
+ AML cells, but only
Rao et al. Journal of Translational Medicine 2011, 9:71
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+ AML cells.( A) Primary CD34
+ cells isolated from BMMCs or PBMCs of 9 AML
patients and 8 healthy donors were isolated and subjected to flow cytometry to determine the purity of CD34
+ cells. (B) 3 CD34
+ AML and 3
CD34
+ normal samples were treated with different concentrations of curcumin (0, 10, 20, 40, and 80 μM) for 24 h. The same CD34
+ AML
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+ hematopoietic
progenitors (Figure 7B). However, CD34
+ cells derived
from the 3 AML patients were insensitive to DNR (Figure
7B). Synergy between curcumin and DNR was examined
in another set of 3 AML patients (patients 7, 8, 9) and 3
healthy donors (donors 6, 7, 8). CD34
+ cells were treated
with curcumin (0, 10, 20, 40, 80 μM) and/or DNR (0.2 μg/
ml) for 48 h. Curcumin at 20, 40, or 80 μM synergistically
enhanced the cytotoxic effect of DNR (0.2 μg/ml) in CD34
+ AML cells, with Q values of 1.60, 1.35 and 1.33, respec-
tively. Normal CD34
+ progenitors were less susceptible to
the combined toxic effects (Figure 7C). 4 AML patients
(patients 4, 5, 6, 7) and 3 donors (donors 4, 5, 6) yielded
sufficient numbers of cells for apoptosis assay by flow
cytometry. As shown in Figure 7D, E, curcumin induced
significant apoptosis in CD34
+ AML cells, but minimal
apoptosis in normal CD34
+ hematopoietic progenitors. 3
AML samples (patients 5, 7, 8) with sufficient cell num-
bers were further analyzed for Bcl-2 protein expression by
Western blotting assay. A dose of 80 μMc u r c u m i nw a s
used in primary CD34
+ AML cells, because curcumin sig-
nificantly down-regulated the Bcl-2 protein levels in CD34
+ AML cell lines at 80 μM. The results showed that treat-
ment with 80 μM curcumin significantly down-regulated
Bcl-2 protein levels (Figure 7F).
Discussion
CD34 positivity has been reported to be an indicator of
poor prognosis in AML [3]. In the present study, we
evaluated the cytotoxicity of curcumin in DNR-insensi-
tive CD34
+ AML cell lines (KG1a and Kasumi-1) and in
CD34
+ primary AML samples. We showed that curcu-
min selectively induced apoptosis in KG1a and Kasumi-
1 cell lines, as well as in primary CD34
+ AML cells, in
association with down-regulation of Bcl-2 expression.
Importantly, co-treatment with curcumin and DNR
synergistically inhibited proliferation, consistent with
decreased Bcl-2 expression. Accordingly, suppression of
Bcl-2 with siRNA increased the susceptibility of KG1a
and Kasumi-1 cells to DNR-induced apoptosis. These
results provide the first evidence for the ability of curcu-
min to overcome insensitivity to DNR by down-regula-
tion of Bcl-2 in CD34
+ AML progenitors.
Insensitivity to chemotherapy is a major obstacle to
cancer treatment. CD34
+ cell lines display natural resis-
tance to mitoxantrone associated with an absence of
apoptosis [9], giving these immature myeloid leukemia
cells a survival advantage over the more mature leuke-
mia hematopoietic compartment. Curcumin induced
apoptosis in more mature HL-60 AML cells by releasing
cytochrome c and activating caspase-3 [18]. The results
of the present study demonstrated that curcumin
induced apoptosis in both DNR-sensitive U937 cells and
DNR-insensitive KG1a and Kasumi-1 cells via the
intrinsic apoptosis pathway involving down-regulation of
Bcl-2 protein, loss of MMP and activation of caspase-3,
followed by PARP degradation. Furthermore, suppres-
sion of Bcl-2 with siRNA caused significant apoptosis,
similar to that seen in curcumin-treated cells, suggesting
an important role for Bcl-2 in curcumin-induced apop-
tosis in these CD34
+AML cell lines.
Accumulating evidence has shown that curcumin
potentiates the effects of chemotherapeutic drugs such
as bortezomib, cisplatin, and 5-fluorouracil plus oxali-
platin (FOLFOX) in vitro and vivo [40-42]. Notably, Yu
et al. revealed that curcumin, either alone or together
with FOLFOX, could effectively eliminate FOLFOX-
resistant colon cancer stem cells (CSCs) [42]. CSCs have
been proposed to be responsible for disease progression
or relapse following conventional therapy [43], and the
results of the current study suggest that curcumin could
act as a potentially powerful chemosensitizing agent in
tumor cells, including CSCs. A recent study indicated
that the combination of curcumin with carnosic acid
also produced a synergistic antiproliferative effect on
KG1a cells; however, this synergism was not associated
with alterations in Bcl-2 levels [44]. In contrast, our
study demonstrated that curcumin synergistically
enhanced the cytotoxic effects of DNR in association
with decreased Bcl-2 expression in KG1a and Kasumi-1
cells. Accordingly, siRNA against Bcl-2 increased the
susceptibility of these CD34
+ cell lines to DNR-induced
apoptosis, indicating that Bcl-2 down-regulation played
an important role in this curcumin-induced synergistic
effect.
Anti-apoptotic Bcl-2 contributes to the survival and
chemoresistance of quiescent leukemia CD34
+ cells [14].
CD34
+ AML cells have higher levels of Bcl-2 gene and
protein than CD34
- AML cells [6]. DNR-induced apop-
tosis can be blocked by Bcl-2 overexpression in DNR-
sensitive CD34
- U937 cells [13]. Conversely, suppression
of Bcl-2 expression with siRNA enhanced DNR-induced
apoptosis in DNR-insensitive CD34
+ KG1a and Kasumi-
1 cells. These results suggest that high levels of Bcl-2
expression could contribute to DNR-insensitivity, and
that down-regulation of Bcl-2 by curcumin could be a
molecular mechanism whereby curcumin can overcome
the insensitivity of CD34
+ AML cells to DNR.
We further demonstrated that primary CD34
+ AML
cells also underwent proliferation inhibition and apopto-
sis with curcumin exposure. This effect was replicated
in 9 individual patient samples representative of differ-
ent French-American-British (FAB) classifications.
Furthermore, curcumin also suppressed Bcl-2 expression
and synergistically enhanced DNR cytotoxicity in pri-
mary CD34
+ AML cells. These primary cells with differ-
ent FAB classifications represented a broad cross-section
of common AML types, suggesting that down-regulation
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be a common death mechanism in CD34
+ AML cells.
Several phase I and phase II clinical trials have indi-
cated the potential therapeutic efficacy and lack of toxic
side effects associated with curcumin [28,29]. However,
its poor bioavailability has limited its use for the treat-
ment of cancers outside the gastrointestinal tract [45].
Modern techniques such as the use of synthetic analogs,
derivatives, different formulations and heat-solubilized
curcumin have been explored with the aim of improving
its bioavailability [46-48]; e.g., the water solubility of
curcumin could be increased 12-fold by heating, without
destroying its biological activity [47,48].
Conclusion
In summary, this study demonstrated a potential new
mechanism whereby curcumin could overcome DNR
insensitivity by down-regulating Bcl-2 in both CD34
+
AML cell lines and in primary CD34
+ AML cells. Cur-
cumin, either alone or in combination with DNR, could
thus be a potential anti-leukemic agent for the treat-
ment of DNR-insensitive CD34
+ AML cells.
Additional material
Additional file 1: Figure S1 Curcumin inhibited clonogenic growth.
(A) The colonies (containing ≥50) were counted after 14 days by light
microscopy (magnification ×40). (B) Results show numbers of colonies in
the curcumin-treated group expressed as a percentage of number of
colonies in the DMSO-treated group. The graph displays the means ± SD
of three independent experiments.
Additional file 2: Figure S2 Morphological changes in nuclei in
curcumin-treated cells. (A) KG1a, Kasumi-1 and U937 cells were
incubated with the indicated concentrations of 0, 40, 60, and 80 μM
curcumin for 24 h. Cells were stained with Hoechst 33342 and then
examined under a light microscope.
Additional file 3: Table S1 Q value. Q values are shown. Q = 0.85-1.15
indicates simple addition; Q > 1.15 indicates synergism.
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